A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study To Assess Safety And Efficacy Of Elad® In Subjects With Alcohol-Induced Liver Decompensation (AILD)

Trial Profile

A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study To Assess Safety And Efficacy Of Elad® In Subjects With Alcohol-Induced Liver Decompensation (AILD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Extracorporeal hepatocyte-based therapy (Primary)
  • Indications Alcoholic hepatitis; Liver failure
  • Focus Therapeutic Use
  • Sponsors Vital Therapies
  • Most Recent Events

    • 03 Aug 2017 Updated baseline characteristics (n=93) presented in a Vital Therapies media release.
    • 03 Aug 2017 According to a Vital Therapies media release, 95 subjects have been enrolled in this trial as of August 2, 2017.
    • 05 Jun 2017 According to a Vital Therapies media release, enrollment criteria for VTL-308 were devised based on extensive analysis of prior clinical data for the ELAD System, including the 203 subject randomized dataset from VTI-208, a prior Phase 3 trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top